Initial Real-World Experiences of Pulmonary Vein Isolation and Ablation of Non-Pulmonary Vein Sites Using a Novel Circular Array Pulsed Field Ablation Catheter.

IF 3 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Joerg Yogarajah, Julie Hutter, Patrick Kahle, Philipp Beaujean, Marko Tomic, Andreas Hain, Samuel Sossalla, Malte Kuniss, Thomas Neumann
{"title":"Initial Real-World Experiences of Pulmonary Vein Isolation and Ablation of Non-Pulmonary Vein Sites Using a Novel Circular Array Pulsed Field Ablation Catheter.","authors":"Joerg Yogarajah, Julie Hutter, Patrick Kahle, Philipp Beaujean, Marko Tomic, Andreas Hain, Samuel Sossalla, Malte Kuniss, Thomas Neumann","doi":"10.3390/jcm13226961","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background and Aims:</b> Various pulsed field ablation (PFA) systems are currently being developed. Recently, a novel CE-approved circular array PFA catheter (PulseSelect™ PFA System, Medtronic, Minneapolis, MN, USA) was introduced. Data on this commercially available system are sparse. The aim was to elucidate real-world data assessing the feasibility, safety, and acute efficacy of pulmonary vein isolation (PVI) and ablation beyond PVI with this novel ablation system. <b>Methods:</b> Consecutive patients with paroxysmal and persistent atrial fibrillation (AF) undergoing first-time ablation with the circular PFA catheter were enrolled in this study. In patients with persistent AF and left atrial (LA) enlargement (LA area > 20 cm<sup>2</sup>), additional left atrial roof ablation (LARA) was performed. Those with concomitant typical atrial flutter received adjunctive cavo-tricuspid isthmus (CTI) ablation. <b>Results:</b> A total of 100 AF patients were included (29% female, 50% persistent AF). Of these, 33 patients (33%) underwent adjunctive LARA, 1 patient (1%) received posterior wall isolation, and 6 patients (6%) required additional CTI ablation. The skin-to-skin procedural time averaged 66.3 ± 13.8 min, while the fluoroscopy time and dose area product were 13.7 ± 4.7 min and 6.8 ± 4.9 Gycm<sup>2</sup>, respectively. Acute PVI was achieved in 100% of pulmonary veins. A bidirectional conduction block of the LARA and CTI lines was confirmed in all patients, and no major adverse events were reported. <b>Conclusions:</b> These real-world data demonstrate the feasibility, safety, and acute efficacy of PVI and ablation beyond PVI using a novel circular array PFA catheter in patients with atrial fibrillation and flutter. The system can easily be integrated with standard PVI workflows. Further and larger studies are warranted to assess the clinical long-term effectiveness and safety of this PFA system.</p>","PeriodicalId":15533,"journal":{"name":"Journal of Clinical Medicine","volume":"13 22","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcm13226961","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Aims: Various pulsed field ablation (PFA) systems are currently being developed. Recently, a novel CE-approved circular array PFA catheter (PulseSelect™ PFA System, Medtronic, Minneapolis, MN, USA) was introduced. Data on this commercially available system are sparse. The aim was to elucidate real-world data assessing the feasibility, safety, and acute efficacy of pulmonary vein isolation (PVI) and ablation beyond PVI with this novel ablation system. Methods: Consecutive patients with paroxysmal and persistent atrial fibrillation (AF) undergoing first-time ablation with the circular PFA catheter were enrolled in this study. In patients with persistent AF and left atrial (LA) enlargement (LA area > 20 cm2), additional left atrial roof ablation (LARA) was performed. Those with concomitant typical atrial flutter received adjunctive cavo-tricuspid isthmus (CTI) ablation. Results: A total of 100 AF patients were included (29% female, 50% persistent AF). Of these, 33 patients (33%) underwent adjunctive LARA, 1 patient (1%) received posterior wall isolation, and 6 patients (6%) required additional CTI ablation. The skin-to-skin procedural time averaged 66.3 ± 13.8 min, while the fluoroscopy time and dose area product were 13.7 ± 4.7 min and 6.8 ± 4.9 Gycm2, respectively. Acute PVI was achieved in 100% of pulmonary veins. A bidirectional conduction block of the LARA and CTI lines was confirmed in all patients, and no major adverse events were reported. Conclusions: These real-world data demonstrate the feasibility, safety, and acute efficacy of PVI and ablation beyond PVI using a novel circular array PFA catheter in patients with atrial fibrillation and flutter. The system can easily be integrated with standard PVI workflows. Further and larger studies are warranted to assess the clinical long-term effectiveness and safety of this PFA system.

使用新型环形阵列脉冲场消融导管进行肺静脉隔离和非肺静脉部位消融的初步实际经验。
背景和目的:目前正在开发各种脉冲场消融(PFA)系统。最近,一种新型的经 CE 认证的圆形阵列 PFA 导管(PulseSelect™ PFA 系统,美敦力公司,美国明尼阿波利斯)问世。有关该商用系统的数据很少。我们的目的是阐明真实世界的数据,评估使用这种新型消融系统进行肺静脉隔离 (PVI) 和 PVI 以外消融的可行性、安全性和急性疗效。方法:首次使用环形 PFA 导管进行消融的阵发性和持续性房颤(AF)患者连续纳入本研究。对于持续性房颤和左心房(LA)增大(LA面积大于20平方厘米)的患者,则进行了额外的左房顶消融术(LARA)。同时伴有典型心房扑动的患者则接受了腔静脉-三尖瓣峡部(CTI)消融术。结果共纳入 100 名房颤患者(29% 为女性,50% 为持续性房颤)。其中,33 名患者(33%)接受了辅助 LARA,1 名患者(1%)接受了后壁隔离,6 名患者(6%)需要额外的 CTI 消融。皮对皮手术时间平均为 66.3 ± 13.8 分钟,透视时间和剂量面积乘积分别为 13.7 ± 4.7 分钟和 6.8 ± 4.9 Gycm2。100%的肺静脉实现了急性 PVI。所有患者均证实 LARA 和 CTI 线路双向传导阻滞,无重大不良事件报告。结论这些实际数据证明了在心房颤动和扑动患者中使用新型环形阵列 PFA 导管进行 PVI 和 PVI 以外消融的可行性、安全性和急性疗效。该系统可轻松与标准 PVI 工作流程集成。有必要进行更多更大规模的研究,以评估该 PFA 系统的临床长期有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Medicine
Journal of Clinical Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
5.70
自引率
7.70%
发文量
6468
审稿时长
16.32 days
期刊介绍: Journal of Clinical Medicine (ISSN 2077-0383), is an international scientific open access journal, providing a platform for advances in health care/clinical practices, the study of direct observation of patients and general medical research. This multi-disciplinary journal is aimed at a wide audience of medical researchers and healthcare professionals. Unique features of this journal: manuscripts regarding original research and ideas will be particularly welcomed.JCM also accepts reviews, communications, and short notes. There is no limit to publication length: our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信